Riskpilot← Back to searchSign inGet full accessNovortex AB
ABActiveOrg 5568506728Vangsby 11Manufacture of medical and dental instruments and supplies · NACE 3250Est. 20110 employees
Revenue 2025
SEK 122K
-25% vs 2024
EBITDA margin
33.7%
+7% vs 2024
Equity ratio
52.8%
Financial strength
Net profit 2025
SEK 33K
-16% vs 2024
| Revenue | SEK 122K | -25% |
| EBITDA | SEK 41K | +7% |
| Net profit | SEK 33K | -16% |
| Total assets | SEK 267K | +35% |
| Equity | SEK 141K | +30% |
| Employees | 0 | — |
Legal name
Novortex AB
Org number
5568506728
Legal form
Aktiebolag
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
26 april 2011
Share capital
SEK 90 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska utveckla produkter och sälja medicinteknisk utrustning samt utföra konsultverksamhet inom sjukvård.
Address
Vangsby 11
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 182 | 159 | 154 | 162 | 122 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 16 | 7 | −19 | 39 | 41 |
| Depreciation & amort. | −1 | −1 | −1 | — | — |
| EBIT | 15 | 6 | −20 | 39 | 41 |
| Net financials | 1 | — | 0 | 0 | 0 |
| Profit before tax | 16 | 6 | −20 | 39 | 41 |
| Tax | −0 | −0 | — | — | −8 |
| Net profit | 16 | 6 | −20 | 39 | 33 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 281 | 298 | 144 | 198 | 267 |
| Equity | 195 | 201 | 69 | 108 | 141 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 86 | 97 | 75 | 90 | 126 |
| Total debt | 86 | 97 | 75 | 90 | 126 |
EBITDA margin
33.7%
This company
15.8%
Market median
+113% vs market
20212025
Equity ratio
52.8%
This company
38.2%
Market median
+38% vs market
20212025
Return on equity
23.2%
This company
18.4%
Market median
+26% vs market
20212025
Net profit margin
26.9%
This company
8.1%
Market median
+232% vs market
20212025
Asset turnover
0.46×
This company
1.12×
Market median
-59% vs market
20212025
Debt / equity
0.89×
This company
0.62×
Market median
+44% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TA Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Novortex AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torbjörn Andréas Lundin | Chief Executive Officer | 0 companies |
| Anders Erik Westermark | Chairman | 0 companies |
| Folke Torbjörn Lundin | Deputy Board Member | 0 companies |
| Leif Martin Belin | Chairman | 0 companies |